Local biotechnology is an industry with high added value that generates exports for more than US$ 216 million and “positions Argentina in the world,” highlighted today the Secretary of Industry and Productive Development, José Ignacio de Mendiguren, when contemplating that the country is one of 12 that produces vaccines.
This was expressed by De Mendiguren after a working meeting with biotechnology companies and startups grouped in the Argentine Chamber of Biotechnology (CAB), to promote the high added value of the sector.
“This industry has a very important objective for the country because it positions Argentina in the world since there are not many countries that produce biotechnology, and these companies brought together in a chamber realize our potential as a country, raises pride and self-esteem to Argentines,” the official said in a statement.
In this sense, he assured: “With the team headed by (Economy Minister) Sergio Massa, we are very clear that Argentina is going ahead by producing, generating a productive matrix that is different from the traditional one, and you are a key sector for that structural change.”
For his part, the vice president of the CAB, Sebastián Bagó, pointed out that “currently the Chamber has 35 mature companies, 92 startups and three accelerators, and these 35 represent US$726 million in billing, US$216 million in exports, plus than 18,000 direct jobs, more than 650 people doing research and development (R&D) and invest 4.6% of their turnover in R&D, which is more than triple the industrial average”.
He also highlighted: “We are an engine of economic growth and for our industry it is important to have promotion and support instruments, which is why this relationship with the Ministry of Industry is very relevant so that we can exchange opinions and information.”
The meeting was held at the plant of the firm mAbxience, a leader in the production of monoclonal antibodies that plans to triple its production capacity by March 2024.
De Mendiguren toured the plant of said company, accompanied by the Chief of Staff of the Secretariat of Industry and Productive Development, Gabriel Vienni; the Undersecretary of Industry, Priscila Makari; and the national directors of SME Financing, Francisco Abramovich, and SME Policy and Management, Pablo Bercovich.
mAbxience, which is dedicated to the development, manufacture and commercialization of biotechnological products for human medicine and is currently in the midst of an expansion stage with the aim of tripling its productive capacity by March 2024.
Source: Ambito
